Amit Singal, MD
Hepatology · Dallas, TXNPI 1073653622
Payments from drug & device makers
Across 463 payments — averaging $3415.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fujifilm Healthcare Americas Corporation$756K
- Roche Diagnostics International Ltd$256K
- AstraZeneca$117K
- Bayer$71K
- Eisai Inc.$60K
- Astrazeneca UK Limited$51K
- plus $271K from 20 others
Across 3 payments — averaging $723.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$2K
What the payments were for
- Consulting fees$411,08877%
- Speaking & faculty fees$31,3236%
- Travel & lodging$79,49415%
- Food & beverage$7,8441%
- Education$7850%
- Charitable contribution$3,0001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fujifilm Healthcare Americas Corporation | 11 | $755,603 |
| Roche Diagnostics International Ltd | 3 | $255,950 |
| AstraZeneca | 48 | $116,511 |
| Bayer | 45 | $71,197 |
| Eisai Inc. | 34 | $60,470 |
| Astrazeneca UK Limited | 31 | $50,871 |
| Genentech, Inc. | 28 | $45,458 |
| Fujifilm Corporation | 3 | $44,697 |
| Genentech USA, Inc. | 33 | $38,633 |
| F. Hoffmann-la Roche AG | 6 | $23,854 |
| Boston Scientific | 17 | $20,665 |
| Exelixis Inc. | 29 | $20,111 |
| Bristol Myers Squibb | 1 | $19,100 |
| E.r. Squibb & Sons, L.L.C. | 13 | $14,976 |
| Gilead | 134 | $8,768 |
| Eisai CO., LTD. | 3 | $8,440 |
| Sirtex Medical Inc | 5 | $8,280 |
| Exact Sciences | 6 | $7,060 |
| Merck | 2 | $4,575 |
| Boehringer Ingelheim | 1 | $2,090 |
| Fujifilm Wako Diagnostics U.S.A. Corporation | 5 | $1,667 |
| Progenics Pharmaceuticals, Inc. | 1 | $1,500 |
| Abbott | 1 | $938 |
| Roche Molecular Systems, Inc. | 1 | $49 |
| AbbVie | 1 | $41 |
| Madrigal Pharmaceuticals | 1 | $39 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENVIMA$52,778
- TECENTRIQ$44,501
- IMFINZI$41,766
- Stivarga$31,262
- Cabometyx$19,480
- Nexavar$15,385
- OPDIVO$14,806
- SIR-Spheres Microspheres$8,204
- General - Interventional Oncology$7,563
- TheraSphere Administration Set$7,200
- Non-Covered$6,650
- Cologuard Collection Kit$4,800
- TheraSphere Y90 Glass Microspheres 7.0 GBq (US Commercial)$4,500
- Elecsys Troponin T Gen 5 STAT$3,150
- uTASWako AFP-L3$2,971
- Avastin$2,845
- CD cobas Reagents$2,800
- Alecensa$2,125
- ROZLYTREK$2,125
- Wako HCC Biomarker(s) DCP and AFP-L3$1,619
How this compares
$1,581,545 in reported general payments places this provider in the 90th percentile of 22 hepatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VemlidyTenofovir Alafenamide | 12 | $15,253 |
| Pantoprazole Sodium | 20 | $268 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadVemlidy | $8,768 | $15,25312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 22 hepatology providers in Texas.
Other hepatology in Dallas
- Marlyn MayoDallas$954K
- William LeeDallas$925K
- Robert RahimiDallas$658K
- Willis MaddreyDallas$289K
- Gary DavisDallas$9K
- Maria Lepe-SuasteguiDallas$4K
- Ussama GhummanDallas$1K
- Sarah LieberDallas$285
- Rashmee PatilMcAllen$3.3M
- Hesham ElgouhariDenison$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.